ASCO 2021 | Role of perceived side effects on treatment decision-making in older patients with AML

Thomas W. LeBlanc, MD, MA, Duke Cancer Institute, Durham, NC, discusses the results of a mixed-methods study that aimed to investigate how older patients with acute myeloid leukemia (AML) approach the decision-making process before they receive treatment. This study interviewed patients and their family members to gain an insight into the role of perceived side effects on treatment decision-making. Participants were predominantly concerned about the presence of adverse side effects such as vomiting, hair loss, organ failure, and death. Side effects had a greater impact on decision-making for patients who were not on treatment and their relatives compared to those with experience of non-intensive therapy. Patient perceptions of the severity and prevalence of side effects were worse than what patients receiving treatment actually experienced. Dr LeBlanc concludes by highlighting the importance of open discussion of treatment options, potential toxicities, and supportive care available. This interview was conducted at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.